STOCK WATCH

■ SCANCELL cashed in on a deal to develop and commercialise an antibody to treat diseases such as cancer. The clinical stage biotech group signed a licence agreement in October with the Danish company Genmab – being paid £5.3m a month later. But the cost of investing in research and development meant it made a loss of £3.2m in the six months to October. It had £24m of cash at the end of October, down from £28.7m in April. Its shares fell 8pc, or 2p, to 23p.